{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:47:10Z","timestamp":1791499630867,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier","isbn-type":[{"value":"9780443432729","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.acr.2026.01.012","type":"book-chapter","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:32:54Z","timestamp":1770669174000},"page":"393-417","source":"Crossref","is-referenced-by-count":1,"title":["Future perspectives and challenges for identification and recognition of clinically significant cancer biomarkers"],"prefix":"10.1016","author":[{"given":"Shiv","family":"Charan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Khanra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash","family":"Medhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/bs.acr.2026.01.012_bib1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/pharmaceutics15061630","article-title":"Biomarkers as biomedical bioindicators: Approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases","volume":"15","author":"Ahmad","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.012_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cpt.2554","article-title":"Biomarker qualification at the European medicines agency: A review of biomarker qualification procedures from 2008 to 2020","volume":"112","author":"Bakker","year":"2022","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/bs.acr.2026.01.012_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-4757-3587-1_3","article-title":"Early detection of ovarian cancer: Promise and reality","author":"Bast","year":"2002","journal-title":"Ovarian Cancer"},{"key":"10.1016\/bs.acr.2026.01.012_bib4","unstructured":"Brigham & Women\u2019s Hospital & Harvard Medical School Chin Lynda 9 11 Park Peter J. 12 Kucherlapati Raju 13, Genome data analysis: Baylor College of Medicine Creighton Chad J. 22 23 Donehower Lawrence A. 22 23 24 25, Institute for Systems Biology Reynolds Sheila 31 Kreisberg Richard B. 31 Bernard Brady 31 Bressler Ryan 31 Erkkila Timo 32 Lin Jake 31 Thorsson Vesteinn 31 Zhang Wei 33 Shmulevich Ilya 31, Oregon Health & Science University Anur Pavana 37 Spellman Paul T. 37. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61\u201370."},{"key":"10.1016\/bs.acr.2026.01.012_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/bs.acc.2024.10.004","article-title":"Multiomics in cancer biomarker discovery and cancer subtyping","volume":"124","author":"Choi","year":"2025","journal-title":"Advances in Clinical Chemistry"},{"key":"10.1016\/bs.acr.2026.01.012_bib6","unstructured":"Cinat, D. (no date). From radiation damage to regeneration using salivary gland organoids: unraveling the underlying signaling pathways."},{"issue":"10","key":"10.1016\/bs.acr.2026.01.012_bib7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nature Medicine"},{"issue":"8","key":"10.1016\/bs.acr.2026.01.012_bib8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid biopsy: Monitoring cancer-genetics in the blood","volume":"10","author":"Crowley","year":"2013","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2026.01.012_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2026.01.012_bib10","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-09-2167","article-title":"Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents","volume":"16","author":"Dancey","year":"2010","journal-title":"Clinical Cancer Research"},{"issue":"19","key":"10.1016\/bs.acr.2026.01.012_bib11","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jnci\/djq306","article-title":"Cancer biomarkers: Can we turn recent failures into success?","volume":"102","author":"Diamandis","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"10.1016\/bs.acr.2026.01.012_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: Genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.acr.2026.01.012_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/11772719231204508","article-title":"Multiomic approaches for cancer biomarker discovery in liquid biopsies: Advances and challenges","volume":"18","author":"Diaz","year":"2023","journal-title":"Biomarker Insights"},{"issue":"14","key":"10.1016\/bs.acr.2026.01.012_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.acr.2026.01.012_bib15","article-title":"Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study","author":"Duan","year":"2025","journal-title":"The Innovation"},{"issue":"7751","key":"10.1016\/bs.acr.2026.01.012_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41586-019-1049-y","article-title":"Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH+","volume":"568","author":"Eng","year":"2019","journal-title":"Nature"},{"key":"10.1016\/bs.acr.2026.01.012_bib17","unstructured":"FDA-NIH Biomarker Working Group, FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US). (2016)."},{"issue":"5","key":"10.1016\/bs.acr.2026.01.012_bib18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/cpt.2795","article-title":"Pharmacodynamic biomarkers for biosimilar development and approval: A workshop summary","volume":"113","author":"Florian","year":"2023","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.012_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1559-0275-10-13","article-title":"Translation of proteomic biomarkers into FDA approved cancer diagnostics: Issues and challenges","volume":"10","author":"F\u00fcz\u00e9ry","year":"2013","journal-title":"Clinical Proteomics"},{"issue":"3","key":"10.1016\/bs.acr.2026.01.012_bib20","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Translational Cancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.012_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2026.01.012_bib22","first-page":"1","article-title":"Regulatory, translational, and operational considerations for the incorporation of biomarkers in drug development","author":"Hatcher","year":"2025","journal-title":"Therapeutic Innovation & Regulatory Science"},{"issue":"2","key":"10.1016\/bs.acr.2026.01.012_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.012_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-025-02434-2","article-title":"Integrating AI and RNA biomarkers in cancer: Advances in diagnostics and targeted therapies","volume":"23","author":"Hussen","year":"2025","journal-title":"Cell Communication and Signaling"},{"issue":"5","key":"10.1016\/bs.acr.2026.01.012_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/cmrp.cmrp_78_23","article-title":"Comprehensive overview of biomarkers to predict response to immune checkpoint therapy in lung cancer","volume":"13","author":"Jain","year":"2023","journal-title":"Current Medicine Research and Practice"},{"issue":"8","key":"10.1016\/bs.acr.2026.01.012_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s43018-020-0087-6","article-title":"Pan-cancer image-based detection of clinically actionable genetic alterations","volume":"1","author":"Kather","year":"2020","journal-title":"Nature Cancer"},{"issue":"9","key":"10.1016\/bs.acr.2026.01.012_bib27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Annals of Oncology"},{"issue":"08","key":"10.1016\/bs.acr.2026.01.012_bib28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/CM9.0000000000003101","volume":"137","author":"Li","year":"2024","journal-title":"Chinese Medical Journal"},{"issue":"3","key":"10.1016\/bs.acr.2026.01.012_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.trecan.2024.12.001","article-title":"Artificial intelligence-based biomarkers for treatment decisions in oncology","volume":"11","author":"Ligero","year":"2025","journal-title":"Trends in Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2026.01.012_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nature Reviews. Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2026.01.012_bib31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/JTO.0b013e318290868f","volume":"8","author":"Lindeman","year":"2013","journal-title":"Journal of Thoracic Oncology"},{"issue":"21","key":"10.1016\/bs.acr.2026.01.012_bib32","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.012_bib33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: Current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"6","key":"10.1016\/bs.acr.2026.01.012_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/cts.12488","article-title":"The role of public\u2013private partnerships in catalyzing the critical path","volume":"10","author":"Maxfield","year":"2017","journal-title":"Clinical and Translational Science"},{"issue":"16","key":"10.1016\/bs.acr.2026.01.012_bib35","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"issue":"34","key":"10.1016\/bs.acr.2026.01.012_bib36","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1200\/JCO.2012.42.6858","article-title":"Publication of tumor marker research results: The necessity for complete and transparent reporting","volume":"30","author":"McShane","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.acr.2026.01.012_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1210164","article-title":"Immune escape and resistance to immunotherapy in mismatch repair deficient tumors","volume":"14","author":"Mestrallet","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"23","key":"10.1016\/bs.acr.2026.01.012_bib38","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.3390\/cancers15235616","article-title":"Clonal neoantigen: Emerging \u201cmechanism-based\u201d biomarker of immunotherapy response","volume":"15","author":"Nemunaitis","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/bs.acr.2026.01.012_bib39","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nmeth.3144","article-title":"Proteogenomics: Concepts, applications and computational strategies","volume":"11","author":"Nesvizhskii","year":"2014","journal-title":"Nature Methods"},{"key":"10.1016\/bs.acr.2026.01.012_bib40","unstructured":"Olivier, M., Hollstein, M., & Hainaut, P.\u00a0(no date). TP53 mutations in human cancers: Origins, consequences, and. supplementary supplementary supplementary supplementary supplementary supplementary."},{"issue":"27","key":"10.1016\/bs.acr.2026.01.012_bib41","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/bs.acr.2026.01.012_bib42","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1016\/bs.acr.2026.01.012_bib43","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"7329","key":"10.1016\/bs.acr.2026.01.012_bib44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/bs.acr.2026.01.012_bib45","first-page":"1113","article-title":"Translational medicine: Moving from the bench to the bedside","volume":"29","author":"Poste","year":"2011","journal-title":"Nature Biotechnology"},{"issue":"18","key":"10.1016\/bs.acr.2026.01.012_bib46","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.3390\/cancers17182981","article-title":"Cancer biomarkers: Reflection on recent progress, emerging innovations, and the clinical horizon","volume":"17","author":"Qoronfleh","year":"2025","journal-title":"Cancers"},{"issue":"6434","key":"10.1016\/bs.acr.2026.01.012_bib47","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaw1219","article-title":"Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution","volume":"363","author":"Rodriques","year":"2019","journal-title":"Science (New York, N. Y.)"},{"issue":"3","key":"10.1016\/bs.acr.2026.01.012_bib48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5603\/rpor.106487","article-title":"Involvement of lncRNA in cancer diagnosis and prognosis and clinical implications","volume":"30","author":"Saini","year":"2025","journal-title":"Reports of Practical Oncology and Radiotherapy"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.012_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","article-title":"Oncogenic PI3K and its role in cancer","volume":"18","author":"Samuels","year":"2006","journal-title":"Current Opinion in Oncology"},{"issue":"27","key":"10.1016\/bs.acr.2026.01.012_bib50","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with\u2265 2 HER2-directed regimens: Phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"10409","key":"10.1016\/bs.acr.2026.01.012_bib51","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (PATHFINDER): A prospective cohort study","volume":"402","author":"Schrag","year":"2023","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/bs.acr.2026.01.012_bib52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJM200507143530217","article-title":"EGFR mutation conferring primary resistance to gefitinib in non\u2013small-cell lung cancer","volume":"353","author":"Shih","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4785","key":"10.1016\/bs.acr.2026.01.012_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science (New York, N. Y.)"},{"issue":"8","key":"10.1016\/bs.acr.2026.01.012_bib54","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1415938","article-title":"Genetic basis for clinical response to CTLA-4 blockade","volume":"372","author":"Snyder","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.acr.2026.01.012_bib55","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"13","key":"10.1016\/bs.acr.2026.01.012_bib56","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","article-title":"Limits to personalized cancer medicine","volume":"375","author":"Tannock","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10.1016\/bs.acr.2026.01.012_bib57","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New England journal of medicine"},{"key":"10.1016\/bs.acr.2026.01.012_bib58","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"161","author":"Van der Hoeven","year":"2017","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.012_bib59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.acr.2026.01.012_bib60","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-25-1793","article-title":"Artificial intelligence and multi-modality data integration deciphers tertiary lymphoid structure maturity in gastric cancer","author":"Wu","year":"2025","journal-title":"Cancer Research"}],"container-title":["Advances in Cancer Research","Biomarkers for Cancer Screening, Diagnosis and Targeted Therapeutic Approaches"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:27:35Z","timestamp":1779298055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X26000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443432729"],"references-count":60,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2026.01.012","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}